Stefan N. Symeonides

机构：NHS Lothian, Edinburgh Cancer Research · ORCID：0000-0002-9892-9314

发表论文 220 篇 · 总被引 4001 次 · h-index 26

代表论文

• Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial (2025 · Nature Medicine · 被引 31)
• International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR (2026 · Journal of Clinical Oncology · 被引 5)
• Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). (2025 · Journal of Clinical Oncology · 被引 5)
• Leveraging knowledge for explainable AI in personalized cancer treatment: challenges and future directions (2025 · Frontiers in Digital Health · 被引 3)
• A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR) (2026 · The Lancet Oncology · 被引 2)
• 2605MO Final efficacy data and biomarker analysis from the clear cell cohort of CALYPSO (2025 · Annals of Oncology · 被引 1)